Prof. Fang Liu is a senior scientist with the Brain Health Imaging Centre and the Tapscott Chair in Schizophrenia Studies at the Centre for Addiction and Mental Health (CAMH). She is also a professor and the director of the Division of Neuroscience and Clinical Translation in the Department of Psychiatry, University of Toronto. She obtained her MD from Shanghai Medical University in China and practiced as a pediatrician before immigrating to Canada. She obtained her MSc and PhD from the Institute of Medical Sciences, University of Toronto. She joined the faculty of the Department of Psychiatry at the University of Toronto in 2001 and was promoted to full professor in 2011. Research in her molecular neuroscience program at CAMH has focused on the identification of novel biomarkers, as well as novel targets for the development of protein-peptide or small molecule therapeutics for the treatment of psychiatric diseases. Her research has led to a number of highly novel and internationally recognized discoveries that are being translated into potential novel therapeutics for treating neuropsychiatric diseases, such as depression, schizophrenia and PTSD.
Prof. Fang Liu is a senior scientist with the Brain Health Imaging Centre and the Tapscott Chair in Schizophrenia Studies at the Centre for Addiction and Mental Health (CAMH). She is also a professor and the director of the Division of Neuroscience and Clinical Translation in the Department of Psychiatry, University of Toronto. She obtained her MD from Shanghai Medical University in China and practiced as a pediatrician before immigrating to Canada. She obtained her MSc and PhD from the Institute of Medical Sciences, University of Toronto. She joined the faculty of the Department of Psychiatry at the University of Toronto in 2001 and was promoted to full professor in 2011. Research in her molecular neuroscience program at CAMH has focused on the identification of novel biomarkers, as well as novel targets for the development of protein-peptide or small molecule therapeutics for the treatment of psychiatric diseases. Her research has led to a number of highly novel and internationally recognized discoveries that are being translated into potential novel therapeutics for treating neuropsychiatric diseases, such as depression, schizophrenia and PTSD.